PMID- 23936148
OWN - NLM
STAT- MEDLINE
DCOM- 20140305
LR  - 20211021
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 7
DP  - 2013
TI  - Effect of folic acid supplementation on levels of circulating Monocyte 
      Chemoattractant Protein-1 and the presence of intravascular ultrasound derived 
      virtual histology thin-cap fibroatheromas in patients with stable angina 
      pectoris.
PG  - e70101
LID - 10.1371/journal.pone.0070101 [doi]
LID - e70101
AB  - BACKGROUND: Virtual Histology Intravascular Ultrasound (VH-IVUS) may be used to 
      detect early signs of unstable coronary artery disease. Monocyte Chemoattractant 
      Protein-1 (MCP-1) is linked with coronary atherosclerosis and plaque instability 
      and could potentially be modified by folic acid treatment. METHODS: In a 
      randomized, prospective study, 102 patients with stable angina pectoris (SAP) 
      received percutaneous coronary intervention and established medical treatment as 
      well as either homocysteine-lowering folic acid/vitamin B12 (+/- B6) or placebo (+/- 
      B6) for 1 year before VH-IVUS was performed. The presence of VH-Thin-Cap 
      Fibroatheroma (VH-TCFA) in non-intervened coronary vessels was registered and 
      serum levels of MCP-1 were measured. The patients were subsequently followed for 
      incident myocardial infarction (MI). RESULTS: Patients treated with folic 
      acid/vitamin B12 had a geometric mean (SD) MCP-1 level of 79.95 (1.49) versus 
      86.00 (1.43) pg/mL for patients receiving placebo (p-value 0.34). VH-TCFA lesions 
      were present in 7.8% of patients and did not differ between intervention arms 
      (p-value 0.47). Serum levels of MCP-1 were 1.46 (95% CI 1.12 to 1.92) times 
      higher in patients with VH-TCFA lesions than in those without (p-value 0.005). 
      Afterwards, patients were followed for median 2.1 years and 3.8% experienced a 
      myocardial infarction (MI), which in post-hoc Cox regression analyses was 
      independently predicted by both MCP-1 (P-value 0.006) and VH-TCFA (p-value 0.01). 
      CONCLUSIONS: In patients with SAP receiving established medical treatment, folic 
      acid supplementation is not associated with either presence of VH-TCFA or levels 
      of MCP-1. MCP-1 is however associated with VH-TCFA, a finding corroborated by 
      increased risk for future MI. ClinicalTrials.gov Identifier: NCT00354081.
FAU - Loland, Kjetil H
AU  - Loland KH
AD  - Department of Clinical Science, University of Bergen, Bergen, Norway. 
      kjetil.loland@gmail.com
FAU - Bleie, Oyvind
AU  - Bleie O
FAU - Strand, Elin
AU  - Strand E
FAU - Ueland, Per M
AU  - Ueland PM
FAU - Nordrehaug, Jan E
AU  - Nordrehaug JE
FAU - Garcia-Garcia, Hector M
AU  - Garcia-Garcia HM
FAU - Serruys, Patrick W
AU  - Serruys PW
FAU - Nygard, Ottar
AU  - Nygard O
LA  - eng
SI  - ClinicalTrials.gov/NCT00354081
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20130725
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (CCL2 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 935E97BOY8 (Folic Acid)
SB  - IM
MH  - Aged
MH  - Angina, Stable/complications/diagnostic imaging/*diet therapy/pathology
MH  - Chemokine CCL2/*blood
MH  - Coronary Vessels/diagnostic imaging/*pathology
MH  - *Dietary Supplements
MH  - Female
MH  - Folic Acid/*administration & dosage
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/diagnostic imaging/etiology/pathology/*prevention & control
MH  - Percutaneous Coronary Intervention
MH  - Plaque, Atherosclerotic/complications/diagnostic imaging/*diet therapy/pathology
MH  - Prospective Studies
MH  - Risk Factors
MH  - Ultrasonography
PMC - PMC3723764
COIS- Competing Interests: Alpharma Inc provided the study capsules, generated the 
      randomization sequence, and concealed the randomization code free of charge and 
      rendered a limited grant to finance the initial phase of the trial. However, 
      Alpharma Inc had no role in the design or implementation of the trial, had no 
      access to study data, and did not participate in data analysis or interpretation 
      or in the preparation, review, or approval of the manuscript. This does not alter 
      our adherence to all the PLOS ONE policies on sharing data and materials.
EDAT- 2013/08/13 06:00
MHDA- 2014/03/07 06:00
PMCR- 2013/07/25
CRDT- 2013/08/13 06:00
PHST- 2013/04/19 00:00 [received]
PHST- 2013/06/15 00:00 [accepted]
PHST- 2013/08/13 06:00 [entrez]
PHST- 2013/08/13 06:00 [pubmed]
PHST- 2014/03/07 06:00 [medline]
PHST- 2013/07/25 00:00 [pmc-release]
AID - PONE-D-13-17226 [pii]
AID - 10.1371/journal.pone.0070101 [doi]
PST - epublish
SO  - PLoS One. 2013 Jul 25;8(7):e70101. doi: 10.1371/journal.pone.0070101. Print 2013.